Antigenics Inc. Earnings Conference Call (Q1 2008)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other May 1 Calls Today's Calls

Call Details Antigenics Inc. Earnings Conference Call (Q1 2008) Thu, May 1, 2008, 11:00 am Eastern Listen to the archived event audio About Antigenics Inc. (NasdaqGM:AGEN) Antigenics, Inc., a biotechnology company, engages in the research and development of technologies and product candidates to treat cancers and infectious diseases. Its investigational product portfolio includes Oncophage (vitespen), a patient-specific therapeutic cancer vaccine approved in Russia; QS-21, an adjuvant being evaluated by its collaborative partners in approximately 15 clinical stage vaccines; Aroplatin (L-NDDP), a liposomal, third-generation platinum chemotherapeutic; and AG-707, a heat shock protein based therapeutic vaccine for the treatment of genital herpes. The company was founded in 1994. It was formerly known as Antigenics L.L.C. and changed its name to Antigenics, Inc. in 2000. Antigenics, Inc. is headquartered in New York, New York. More Info: Quote | Chart | News | Profile | Reports | Research | SEC | Msgs | Insider | Financials | Analyst Ratings